香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 PrimeGenX Therapeutics Co., Ltd. 北京普祺醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。您閱覽本文件，即代表您知悉、 接納並向北京普祺醫藥科技股份有限公司（「本公司」）、其聯席保薦人、整體協調人、顧問或包銷團成員 表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據呈交香港公司註冊處註冊的本公司招 股章程作出投資決定；有關文本將於發售期內向公眾人士刊發。 (i) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件中 的資料作出任何投資決定； (ii) 在聯交所網站登載本文件 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Immunotech Biopharm Ltd 永泰生物製藥有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6978） 有關根據一般授權 發行可換股債券的框架協議 及票據 董 事 會 欣 然 宣 佈，本 公 司 與 投 資 者 就 認 購 新 可 換 股 債 券 及 票 據 訂 立 具 法 律 約 束 力 的 框 架 協 議。認 購 事 項 的 代 價 將 專 項 用 作 全 數 及 最 終 清 償 將 於2026 年2月20日到期的2023年 可 換 股 債 券 的 本 金 額。換 股 股 份 將 根 據 一 般 授 權 發 行，彼 此 之 間 及 與 轉 換 日 期 的 已 發 行 股 份 將 享 有 同 等 地 位。 本 公 司 與 投 資 者 現 正 進 行 磋 商，旨 在 儘 快 落 實 認 購 協 ...

Core Viewpoint - ImmunityBio's stock has surged over 178% this year, with a pre-market increase of over 13% on Tuesday, currently trading at $6.31 per share [1] Group 1: Company Developments - ImmunityBio announced that the FDA is seeking additional information related to its supplemental biologics license application for Anktiva in combination with BCG for treating non-muscle invasive bladder cancer in patients with papillary tumors [1] - The FDA has requested certain additional information to support a potential resubmission of the application initially submitted last year for the papillary indication [1] - The company plans to submit the required information to the FDA within the next 30 days, and the additional information does not involve initiating or designing new clinical trials [1]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The pharmaceutical sector underperformed the overall market this week, with a 0.68% decline in the biotechnology sector compared to a 0.03% increase in the overall A-share market [1] - The report highlights the successful listing of Rebio Biotech on the Hong Kong Stock Exchange, focusing on the small RNA industry and its potential [2] - Rebio Biotech has established a proprietary delivery platform, RiboGalSTAR, and has entered into commercialization partnerships valued at over $2 billion [2] - The core asset RBD4059, targeting FXI, is currently in clinical phase 2a studies in Sweden, showing promise in treating thrombotic diseases [2][21] Summary by Sections Market Performance - The overall A-share market increased by 0.03%, while the Shanghai Composite Index decreased by 0.57%. The biotechnology sector saw a decline of 0.68% [1][26] - Within the biotechnology sector, chemical pharmaceuticals fell by 2.40%, while medical services rose by 3.29% [1][26] Company Overview - Rebio Biotech focuses on small RNA drug development, with seven products in clinical research, four of which are in phase 2 trials [2][9] - The company has a strong management team with extensive experience in drug development and production [16][18] Financial Projections - The report provides earnings forecasts for key companies, with Rebio Biotech's core asset RBD4059 showing significant potential in the thrombotic disease market [3][21] - The report recommends investment opportunities in the CXO sector and highlights the clinical progress of innovative drugs overseas [2][36] Valuation Metrics - The TTM P/E ratio for the pharmaceutical and biotechnology sector is 38.70x, compared to 22.18x for the overall A-share market [31] - Specific sub-sectors show varying P/E ratios, with chemical pharmaceuticals at 47.60x and medical services at 36.15x [31]

Core Viewpoint - The company is actively exploring the potential of its recombinant Staphylococcus aureus vaccine, which currently targets closed orthopedic surgeries, with plans to expand its applications to other clinical indications, particularly pressure ulcers, which affect over 4 million patients annually in China [2] Group 1: Vaccine Development and Market Potential - The recombinant Staphylococcus aureus vaccine has a broad market outlook as it can be extended to multiple departments related to hospital infections [2] - The company has initiated work on the second indication for the vaccine, targeting pressure ulcers, which represents a significant patient population in China [2] Group 2: Infection Statistics and Medical Needs - According to Zhi Shi Consulting, the number of MRSA infections in China is projected to reach 2.3 million cases in 2024, increasing to 2.6 million by 2035, while global MRSA cases are expected to reach 7.4 million by 2035 [2] - The high medical burden of Staphylococcus aureus infections and the growing issue of antibiotic resistance highlight the urgent need for effective vaccines, which remain unmet globally [2] Group 3: International Expansion - The company’s recombinant Staphylococcus aureus vaccine not only has a market foundation in China but also possesses potential for international expansion, with ongoing efforts to pursue related overseas collaborations [2]

证券日报网1月20日讯 ，欧林生物在接受调研者提问时表示，根据全国细菌耐药监测系统的公开数据以 及公司的流调数据等，金黄色葡萄球菌在近五年所有临床细菌分离株中排名前三位，居革兰氏阳性菌首 位；金葡菌中MRSA（耐药金葡菌）检出率在28%-30%之间波动。金葡菌主要感染科室包括：ICU（细 菌感染最集中，是普通病房的三倍以上）、皮肤科和烧伤科（软组织感染）、骨科手术部位感染、呼吸 内科（医院获得性肺炎）等。此外，特种人群（军人、消防战士）的贯穿伤/创伤伤口感染预防也是拓 展方向。 （文章来源：证券日报） ...

Core Viewpoint - The company is progressing normally with the Phase III clinical trial of the gold-staphylococcus vaccine, with no unblinding completed yet and no efficacy data results formed [2] Group 1: Clinical Trial Progress - The company expects to complete the initial and retesting of all serum samples by the end of Q1 this year [2] - Data cleaning is currently underway, with expectations to achieve a phase lock and conduct the first efficacy unblinding after obtaining serum test reports in the first half of this year [2] - The clinical trial progress and results may be influenced by various factors, and the final outcomes will be based on the company's public information [2]

Group 1 - The Hang Seng Index opened with a sharp decline and maintained a weak consolidation throughout the day, closing down by 1.05% [1] - The healthcare sector led the decline, with the Hang Seng Healthcare Index dropping by 2.68%, including significant losses from China Biologic (down 6.19%) and 3SBio (down 5.51%) [3] - The technology sector also faced weakness, with the Hang Seng Technology Index falling by 1.55%, highlighted by Bilibili's drop of 6.85% and Alibaba's decline of 3.49% [3] Group 2 - The banking sector showed relative resilience, with the Hang Seng Bank Index closing down by only 0.67%, despite some individual banks like Chongqing Bank and Standard Chartered experiencing slight declines [3] - Overall, more than 10 stocks in the healthcare sector saw declines exceeding 4%, indicating a broad sell-off in this industry [3] - The performance of major banks such as China Minsheng Bank, Bank of China, and Industrial and Commercial Bank of China also reflected minor losses, contributing to the overall stability of the banking sector [3]

Core Viewpoint - The company is focusing on the clinical application of the recombinant goldenseal vaccine, leveraging its existing promotion network established through the tetanus vaccine [1] Group 1: Clinical Application and Promotion Strategy - The primary use case for the recombinant goldenseal vaccine is clinical application [1] - The company has built a mature promotion network based on the tetanus vaccine promotion system [1] - The company plans to apply the successful experience from the tetanus vaccine to the recombinant goldenseal vaccine [1] Group 2: Market Education and Support - The company aims to support academic research and market education to standardize in-hospital diagnostic processes [1] - This initiative is intended to help reduce antibiotic-resistant bacterial infections [1] - The company is committed to ensuring efficient commercialization of the vaccine [1] Group 3: Sales and Promotion Activities - The sales team will initiate preliminary promotion activities based on the product application status of the recombinant goldenseal vaccine [1]

Core Viewpoint - The company has completed preclinical communication with the National Medical Products Administration (NMPA) regarding a second indication for pressure ulcers and is currently refining related research [1] Group 1 - The company is in the process of finalizing the clinical trial protocol, which will require further communication with the NMPA before submitting for clinical approval [1] - The company anticipates submitting the clinical application this year [1]